Literature DB >> 11698646

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

T Okazaki1, A Maeda, H Nishimura, T Kurosaki, T Honjo.   

Abstract

PD-1 is an immunoreceptor that belongs to the immunoglobulin (Ig) superfamily and contains two tyrosine residues in the cytoplasmic region. Studies on PD-1-deficient mice have shown that PD-1 plays critical roles in establishment and/or maintenance of peripheral tolerance, but the mode of action is totally unknown. To study the molecular mechanism for negative regulation of lymphocytes through the PD-1 receptor, we generated chimeric molecules composed of the IgG Fc receptor type IIB (Fc gamma RIIB) extracellular region and the PD-1 cytoplasmic region and expressed them in a B lymphoma cell line, IIA1.6. Coligation of the cytoplasmic region of PD-1 with the B cell receptor (BCR) in IIA1.6 transformants inhibited BCR-mediated growth retardation, Ca(2+) mobilization, and tyrosine phosphorylation of effector molecules, including Ig beta, Syk, phospholipase C-gamma 2 (PLC gamma 2), and ERK1/2, whereas phosphorylation of Lyn and Dok was not affected. Mutagenesis studies indicated that these inhibitory effects do not require the N-terminal tyrosine in the immunoreceptor tyrosine-based inhibitory motif-like sequence, but do require the other tyrosine residue in the C-terminal tail. This tyrosine was phosphorylated and recruited src homology 2-domain-containing tyrosine phosphatase 2 (SHP-2) on coligation of PD-1 with BCR. These results show that PD-1 can inhibit BCR signaling by recruiting SHP-2 to its phosphotyrosine and dephosphorylating key signal transducers of BCR signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698646      PMCID: PMC61133          DOI: 10.1073/pnas.231486598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  New experimental approaches in retrovirus-mediated expression screening.

Authors:  T Kitamura
Journal:  Int J Hematol       Date:  1998-06       Impact factor: 2.490

2.  Hyperresponsive B cells in CD22-deficient mice.

Authors:  T L O'Keefe; G T Williams; S L Davies; M S Neuberger
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

Review 3.  Inhibitory receptors, ITIM sequences and phosphatases.

Authors:  J C Unkeless; J Jin
Journal:  Curr Opin Immunol       Date:  1997-06       Impact factor: 7.486

4.  Fc gammaRIIB1 inhibition of BCR-mediated phosphoinositide hydrolysis and Ca2+ mobilization is integrated by CD19 dephosphorylation.

Authors:  K L Hippen; A M Buhl; D D'Ambrosio; K Nakamura; C Persin; J C Cambier
Journal:  Immunity       Date:  1997-07       Impact factor: 31.745

5.  Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling.

Authors:  M Ono; H Okada; S Bolland; S Yanagi; T Kurosaki; J V Ravetch
Journal:  Cell       Date:  1997-07-25       Impact factor: 41.582

6.  A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1.

Authors:  D N Burshtyn; W Yang; T Yi; E O Long
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

7.  Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

Authors:  H Nishimura; Y Agata; A Kawasaki; M Sato; S Imamura; N Minato; H Yagita; T Nakano; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

8.  Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.

Authors:  A Maeda; A M Scharenberg; S Tsukada; J B Bolen; J P Kinet; T Kurosaki
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

9.  Activation of two types of Ca2+-permeable nonselective cation channel by endothelin-1 in A7r5 cells.

Authors:  Y Iwamuro; S Miwa; T Minowa; T Enoki; X F Zhang; M Ishikawa; N Hashimoto; T Masaki
Journal:  Br J Pharmacol       Date:  1998-08       Impact factor: 8.739

10.  Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

Authors:  H Nishimura; N Minato; T Nakano; T Honjo
Journal:  Int Immunol       Date:  1998-10       Impact factor: 4.823

View more
  292 in total

Review 1.  B cell inhibitory receptors and autoimmunity.

Authors:  Nicholas R Pritchard; Kenneth G C Smith
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

2.  Programmed cell death-1 single-nucleotide polymorphism rs10204525 is associated with human immunodeficiency virus type 1 RNA viral load in HIV-1-infected Moroccan subjects.

Authors:  Hanâ Baba; Anass Kettani; Meryem Bouqdayr; Ahd Ouladlahsen; Rajaa Bensghir; Latifa Marih; Mustapha Sodqi; Soumaya Benjelloun; Sayeh Ezzikouri; Imane Zaidane; Fatima-Zahra Jadid; Kamal Marhoum El Filali; Lahcen Wakrim
Journal:  Med Microbiol Immunol       Date:  2021-05-24       Impact factor: 3.402

Review 3.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

Review 4.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

5.  Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.

Authors:  Janine Gotot; Catherine Gottschalk; Sonny Leopold; Percy A Knolle; Hideo Yagita; Christian Kurts; Isis Ludwig-Portugall
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

Review 6.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

7.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Authors:  Jang-June Park; Ryusuke Omiya; Yumiko Matsumura; Yukimi Sakoda; Atsuo Kuramasu; Mathew M Augustine; Sheng Yao; Fumihiko Tsushima; Hidehiko Narazaki; Sudarshan Anand; Yingjia Liu; Scott E Strome; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 8.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 9.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

10.  The inhibitory potential of Fc receptor homolog 4 on memory B cells.

Authors:  Gotz R A Ehrhardt; Randall S Davis; Joyce T Hsu; Chuen-Miin Leu; Annette Ehrhardt; Max D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.